IFA
MREO

Index Fund Advisors’s Mereo BioPharma MREO Stock Holding History

Index Fund Advisors’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,000
Closed -$99K – 99
2024
Q1 		$99K Buy
+30,000
New +$102K 0.01% 95

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Index Fund Advisors's MREO Position: Q2 2024 in Review

Index Fund Advisors sold out of Mereo BioPharma (MREO) in Q2 2024, closing a stake of 30,000 shares — an estimated $99K sold.

Index Fund Advisors first reported a position in MREO in Q1 2024 and held it in 1 quarter. The position peaked at $99K in Q1 2024. 79 funds tracked by Wall St. Rank hold MREO as of Q2 2024.

  • Index Fund Advisors reported no remaining Mereo BioPharma position as of Q2 2024 after selling out during the quarter.
  • Index Fund Advisors sold 30,000 Mereo BioPharma shares in Q2 2024, an estimated $99K.
  • Index Fund Advisors first reported a position in Mereo BioPharma in Q1 2024 and held it in 1 quarter.
  • Index Fund Advisors's Mereo BioPharma position peaked at $99K in Q1 2024.
  • 79 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2024.

Based on Index Fund Advisors's 13F filing for Q2 2024, filed 2 Aug 2024.